Literature DB >> 1154799

The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans.

D E Case, P R Reeves.   

Abstract

1. 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine (I.C.I. 58,834) in three 14C-labelled forms, given orally to two male volunteers, was completely absorbed, extensively metabolized and rapidly eliminated via the kidney. 2. O-Dealkylation, the major metabolic pathway in the rat, was not significant in man. 3. The major component in blood at all times was I.C.I. 58,834, which had a blood half-life of 4 h. The level of 14C in blood at 31 h was near the limit of detection. 4. The observed activity of the drug appears to be due to the parent compound alone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1154799     DOI: 10.3109/00498257509056097

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  11 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.

Authors:  F Pisani; A Fazio; E Spina; C Artesi; B Pisani; M Russo; R Trio; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man.

Authors:  G Cocchiara; R Battaglia; P Pevarello; M Strolin Benedetti
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jul-Sep       Impact factor: 2.441

Review 4.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 5.  Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-06       Impact factor: 9.546

6.  Choosing an antidepressant.

Authors:  D E Case
Journal:  Br Med J       Date:  1978-05-13

7.  Determination of viloxazine in plasma by GLC.

Authors:  T R Norman; G D Burrows; B M Davies; J M Wurm
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

8.  Pharmacokinetics of viloxazine hydrochloride in man.

Authors:  B Vandel; S Vandel; J M Jounet; D Blum
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

9.  Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications.

Authors:  A C Altamura; T Melorio; G Invernizzi; F Colacurcio; R Gomeni
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

Review 10.  Chirality and drugs used in psychiatry: nice to know or need to know?

Authors:  R M Lane; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.